Good Therapeutics

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.

Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Good Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $1.1B in funding across 36 round(s). With a team of 11-50 employees, Good Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Good Therapeutics, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.